FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,971,382 | -52.3% | 834,324 | -42.8% | 0.02% | -53.7% |
| Q1 2023 | $8,317,913 | +55.2% | 1,459,283 | +174.8% | 0.04% | +36.7% |
| Q4 2022 | $5,358,153 | -54.2% | 531,036 | +1.6% | 0.03% | -52.4% |
| Q3 2022 | $11,711,000 | -1.2% | 522,574 | +9.3% | 0.06% | +3.3% |
| Q2 2022 | $11,849,000 | +39.7% | 478,153 | +118.6% | 0.06% | +27.1% |
| Q1 2022 | $8,480,000 | -46.3% | 218,718 | -19.0% | 0.05% | -44.8% |
| Q4 2021 | $15,805,000 | +114.1% | 270,120 | +116.9% | 0.09% | +81.2% |
| Q3 2021 | $7,382,000 | +742.7% | 124,546 | +1133.3% | 0.05% | +700.0% |
| Q2 2021 | $876,000 | -72.6% | 10,099 | -71.3% | 0.01% | -77.8% |
| Q4 2020 | $3,202,000 | +186.4% | 35,218 | +25.9% | 0.03% | +200.0% |
| Q3 2020 | $1,118,000 | +47.3% | 27,965 | -18.1% | 0.01% | -59.1% |
| Q1 2020 | $759,000 | – | 34,166 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |